Legend Biotech CARVYKTI® Sales Hit $524M
Ticker: LEGN · Form: 6-K · Filed: Oct 14, 2025 · CIK: 1801198
| Field | Detail |
|---|---|
| Company | Legend Biotech Corp (LEGN) |
| Form Type | 6-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $524 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: sales-update, pharmaceuticals, collaboration
TL;DR
Legend Biotech prelim sales for CARVYKTI® were $524M last quarter.
AI Summary
Legend Biotech Corporation announced preliminary net sales for CARVYKTI® of approximately $524 million for the quarter ended September 30, 2025. This announcement was made on October 14, 2025, and is pursuant to a collaboration and license agreement with Janssen Biotech, Inc. and Janssen Pharmaceutica NV.
Why It Matters
This preliminary sales figure for CARVYKTI® provides an early look at the drug's commercial performance, which is crucial for investors assessing Legend Biotech's revenue growth and market traction.
Risk Assessment
Risk Level: low — This is a routine sales update filing and does not introduce new material risks.
Key Numbers
- $524 million — CARVYKTI® Net Sales (Preliminary sales for the quarter ended September 30, 2025)
Key Players & Entities
- Legend Biotech Corporation (company) — Registrant
- CARVYKTI® (product) — Drug for which sales are reported
- $524 million (dollar_amount) — Preliminary net sales for the quarter
- September 30, 2025 (date) — End of the reporting quarter
- October 14, 2025 (date) — Date of the report
- Janssen Biotech, Inc. (company) — Collaboration partner
- Janssen Pharmaceutica NV (company) — Collaboration partner
FAQ
What is the total net trade sales for CARVYKTI® for the quarter ended September 30, 2025?
Legend Biotech announced preliminary net trade sales of approximately $524 million for the quarter ended September 30, 2025.
When was this sales update filed with the SEC?
This Form 6-K was filed on October 14, 2025.
Who are Legend Biotech's partners in the CARVYKTI® collaboration?
Legend Biotech's partners are Janssen Biotech, Inc. and Janssen Pharmaceutica NV (together, 'Janssen').
What is the standard industrial classification for Legend Biotech Corp?
The standard industrial classification for Legend Biotech Corp is Pharmaceutical Preparations [2834].
What is the fiscal year end for Legend Biotech Corp?
The fiscal year end for Legend Biotech Corp is December 31.
Filing Stats: 742 words · 3 min read · ~2 pages · Grade level 18.4 · Accepted 2025-10-14 07:30:49
Key Financial Figures
- $524 million — CARVYKTI ® generated approximately $524 million in net trade sales during the quarter e
Filing Documents
- f6k_101425.htm (6-K) — 14KB
- 0001171843-25-006413.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LEGEND BIOTECH CORPORATION Date: October 14, 2025 By: /s/ Ying Huang Name: Ying Huang, Ph.D. Title: Chief Executive Officer